Safety of Infliximab Treatment in Patients with Rheumatoid Arthritis in a Real-world Clinical Setting: Description and Evaluation of Infusion Reactions

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Rheumatology

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3899/jrheum.110956PMID 22589260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The safety of infliximab infusions in the community setting.

  2010cited by this paper
• Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

  2007cited by this paper
• - 1-Predictors of infusion reactions during infliximab treatment in patients with arthritis

  2006cited by this paper
• Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology.

  2006cited by this paper
• Predictors of infusion reactions during infliximab treatment in patients with arthritis

  2006cited by this paper
• The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.

  2006cited by this paper
• Monoclonal antibodies, immunogenicity, and associated infusion reactions.

  2005cited by this paper
• Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.

  2004cited by this paper
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

  2004cited by this paper
• Original contributionThe incidence and management of infusion reactions to infliximab: a large center experience

  2003cited by this paper
• The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience

  2003cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper

• Safety of Anti-TNFs in Patients with Immune-Mediated Disease

  2022cites this paper
• Infliximab in inflammatory bowel disease. Is premedication necessary?

  2021cites this paper
• Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017

  2021cites this paper
• Infliximab in inflammatory bowel disease. Is premedication necessary?

  2020cites this paper
• Repeated infliximab injection may shift delayed infusion reactions to acute infusion reactions in patients with psoriasis

  2020cites this paper
• Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis.

  2019cites this paper
• Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting

  2018cites this paper
• Cutaneous Manifestations of Reactions to Biologics

  2018cites this paper
• Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study

  2017cites this paper
• Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences

  2017cites this paper
• Cohort Study Children with Refractory Arthritis and / or Uveitis : A Retrospective Longitudinal Prevalence of Anti-infliximab Antibodies and Their Associated Cofactors in

  2016cites this paper
• Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients*

  2016cites this paper
• Anti-TNF-&agr; Agent Infliximab and Splenectomy Are Protective Against Renal Ischemia-Reperfusion Injury

  2016cites this paper
• Retention on anti-tumour necrosis factor therapy: the Waikato experience.

  2015cites this paper
• Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry

  2015cites this paper
• Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years.

  2015cites this paper
• IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment

  2015cites this paper
• Prospective Real-world Community Registry Incidence and Management of Infusion Reactions to Infliximab in a

  2015cites this paper
• Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management

  2015cites this paper
• Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years

  2014cites this paper
• Anti-TNF-Alpha Therapy and Systemic Vasculitis

  2014cites this paper
• Safety of anti-tumor necrosis factor therapies in arthritis patients.

  2014cites this paper
• Infusion Reactions Related to Infliximab Therapy Are Not Usually Associated with Drug Discontinuation

  2012cites this paper